6 results match your criteria: "John's Hopkins School of Medicine[Affiliation]"
Eur J Gastroenterol Hepatol
May 2024
Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/NYC Health + Hospitals Queens, New York.
Ann Clin Transl Neurol
April 2024
Women and Child Institute, John's Hopkins Aramco Healthcare (Jhah), Dhahran, Saudi Arabia.
Parkinsonism-dystonia-2 PKDYS2 is an autosomal-recessive disorder, caused by pathogenic biallelic variants in SLC18A2 which encodes the vesicular monoamine transporter (VMAT2) protein. PKDYS2 is a treatable neurotransmitter disease, and the rate of diagnosis of this disorder has increased significantly with the advance of genomic technologies. Our report highlights a novel pathologic variant in one case and a novel finding on MRI Brain, consisting of a normal symmetrical signal intensity in the dorsal brainstem and pons, and it substantiates the significance of genetic testing in the evaluation of children with developmental delays, which influences clinical decisions to enhance patient outcomes.
View Article and Find Full Text PDFObjective: To examine the factors associated with increased deoxyribonucleic acid fragmentation index (DFI), evaluate the pregnancy outcomes of men with increased DFI, and compare three independent DFI assays.
Design: Secondary analysis.
Setting: Nine US-based fertility centers.
Semin Musculoskelet Radiol
December 2020
The Institute of Cancer Research, London, United Kingdom.
Schizophr Res
April 2019
Department of Psychiatry, University of Illinois, Chicago, IL 60607, USA.
Background: Studies have hypothesized that immunological abnormalities might contribute to schizophrenia, and basic science studies, as well as several clinical trials suggest that minocycline could be efficacious in ameliorating both positive and negative symptoms of schizophrenia. In this study we examined the effect of minocycline on schizophrenia in a large randomized controlled trial.
Methods: We performed a 16-week, multi-center, double-blind, randomized, placebo-controlled study on 200 subjects with schizophrenia or schizoaffective disorder randomized to receive either minocycline (200 mg/day, n = 100), or placebo (n = 100) as an add-on to anti-psychotic treatment.
J Cardiothorac Vasc Anesth
April 1993
Department of Anesthesiology, John's Hopkins School of Medicine, Baltimore, MD.